LifeSci Capital analyst Sam Slutsky initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $90 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics initiated with a Buy at Truist
- Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes
- Palvella Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Trial and Market Potential
- Palvella Therapeutics completes enrollment in Phase 3 SELVA trial
- Palvella Therapeutics granted sixth U.S. patent covering rapamycin